G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$3.19 USD
+0.20 (6.69%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Brokerage Reports
0 items in cart
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 81 - 100 ( 356 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
2Q22 Results; Cosela Sales Exceed Our Expectations; Clinical Trial Data From Five Studies Over the Next 18 Months
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
2Q22: Sequential COSELA Revenue Growth Continues with In-House Sales-$35PT
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Our Updated COSELA Revenue Estimates Ahead of the Q2 Report
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Cosela Receives Approval in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in ES-SCLC Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Complete Enrollment Announced In Phase 3 PRESERVE 1 Trial of Cosela in mCRC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Cosela For ES-SCLC Post-Hoc Analysis Data Presented at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Trilaciclib Suppresses Myelosuppression at ASCO
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
KOL Webinar: A Clinical Perspective of Using COSELA in the Treatment of Cancer Patients
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
KOL Webinar Wednesday, May 25, 2022 at 12:00 pm ET with Dr. Jared Weiss
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T